Month: June 2021

HOUSTON, June 11, 2021 (GLOBE NEWSWIRE) — SEACOR Marine Holdings Inc. (NYSE:SMHI) (the “Company” or “SEACOR Marine”), a leading provider of marine and support transportation services to offshore energy facilities worldwide, announced that Falcon Global USA LLC (“FGUSA”), an indirect subsidiary of SEACOR Marine, entered into a second amendment and conditional payoff agreement (the “Conditional Payoff Agreement”) in respect of the credit facility of FGUSA, as borrower, and certain of its subsidiaries, dated as of February 8, 2018 administered by JPMorgan Chase Bank, N.A. (as amended, the “FGUSA Credit Facility”). As of June 10, 2021, there was $117.3 million of principal outstanding under the FGUSA Credit Facility. Under the terms of the Conditional Payoff Agreement, the $117.3 million of principal currently outstanding will be deemed...

                                                          Villers-lès-Nancy, 11 June 2021 – 12:00 p.m. (CET) PRESS RELEASE ORDINARY ANNUAL GENERAL MEETING MEETING NOTICE ON-LINE AVAILABILITY OF MEETING MATERIALS PHARMAGEST INTERACTIVE hereby provides notice to shareholders of the Ordinary Annual General Meeting to be held on Tuesday, 29 June 2021 at 5 p.m., at the Company’s registered office located in VILLERS-LÈS-NANCY (Technopôle de Nancy-Brabois – 5 Allée de Saint Cloud). IMPORTANT NOTICE – COVID-19 Despite the continuing health crisis linked to the COVID-19 epidemic, in light of the number of persons normally present at the Company’s general meetings and the characteristics of the meeting rooms of the Company’s registered office, on the one hand, and the goal of promoting dialogue with shareholders on the other hand, the...

BEIJING, China, June 11, 2021 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced the closing of its public offering of 6,500,000 American Depositary Shares (“ADSs”), each representing 15 Class A ordinary shares of the Company, at a public offering price of US$24.50 per ADS. The Company granted the underwriters a 30-day option to purchase up to an aggregate of 975,000 additional ADSs from the Company at the public offering price. The underwriters fully exercised their option to purchase these additional ADSs. The Company expects to use the net proceeds from the ADS offering to (i) expand its customer base and drive customer engagement with its services, (ii) invest in expanding its products, services and technologies...

  The order of the Tallinn Circuit Court entered into the force, which annulled the fine of the Financial Supervision Authority against Admiral Markets AS. On February 8, 2021, Finantsinspektsioon (FSA) forwarded a decision to Admiral Markets AS notifying the company about an imposed fine. According to the regulator Admiral Markets AS had not acted entirely in accordance with the Securities Market Act, following the crash of Future crude oil prices in April 2020. Admiral Markets AS did not agree with the decision of the FSA and confirmed that it had always acted in the best interests of its clients. The company was confident that regardless of the opinions in the FSA announcement, it operated in accordance with the regulatory framework even when faced with unusual circumstances. Taken all that into consideration, Admiral Markets AS filed...

Orphazyme A/SCompany announcement        No. 15/2021Company Registration No. 32266355Copenhagen – June 11, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American Depositary Shares (ADSs) representing its ordinary shares on Nasdaq US have since June 10, 2021 experienced extreme volatility in price and trading volume. The company is not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume that has occurred since June 10, 2021. Investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines. Orphazyme’s...

Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from the Phase 2a HOPE-KIDS 1 Study that showed children with sickle cell disease (SCD) ages 4 to 11 years treated with Oxbryta® (voxelotor) tablets experienced significant improvements in hemoglobin levels. These data, along with results from two real-world evidence studies of Oxbryta, will be presented at the European Hematology Association (EHA) 2021 Virtual Congress, taking place online June 9-17, 2021. “The encouraging results seen with Oxbryta treatment in younger patients...

Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress — Ongoing ADVANCE II study evaluating DCP-001 in AML patients is nearing target enrollment of 20 patients —  Immunicum AB (publ; IMMU.ST) today presents clinical data showing DCP-001’s ability to induce immune responses to a broad range of tumor associated antigens in acute myeloid leukemia (AML) patients, as well as preclinical results of enhanced efficacy when combining DCP-001 with established AML treatment regimens, at the EHA 2021 Virtual Congress, held from June 9-17, 2021. The abstracts covering these presentations have been communicated previously. The E-posters can now be accessed through the conference platform and at the Company’s corporate website. “The data presented at the EHA conference underscores...

        New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia        Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningful Findings provide further evidence that sutimlimab results in rapid inhibition of C1-activated hemolysis within one week of treatment and had a sustained treatment effect throughout the studyPARIS – June 11, 2021 – Results from Part A of CADENZA, a pivotal Phase 3 double-blind, placebo-controlled study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) without a recent history...

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast Today at 7:30 a.m. ET – CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported a full analysis of updated data, including patient-reported outcome (PRO) measures, from its global Phase 3 ACTIVATE and ACTIVATE-T studies of mitapivat in adults with pyruvate kinase (PK) deficiency. Data from the studies will be featured in oral presentations on Tuesday, June 15, at the European Hematology Association (EHA) Virtual Congress. Consistent with previously announced topline data, the ACTIVATE and ACTIVATE-T...